美国肝细胞癌发病率、死亡率、治疗及总生存率近期趋势
基于SEER数据库分析美国肝细胞癌(HCC)2000至2022年趋势,发病率2019至2022年下降(APC -3.74%),死亡率2013年后平台期;COVID-19期间治愈性治疗几率降低(aOR 0.87),未治疗几率增加(aOR 1.48),总生存改善暂停(aHR 0.98)。
要点
- HCC发病率2019至2022年下降,死亡率2013年后趋稳。
- COVID-19期间治愈性治疗几率降低,未治疗几率增加。
- 总生存2000至2019年改善,2020至2022年无显著变化。
核心结论
- HCC发病率已开始下降,基于发病率的死亡率趋于平稳。
- COVID-19期间早期检测和治愈性治疗减少,需长期随访评估生存影响。
- 非西班牙裔黑人与白人患者生存差异缩小,可能反映医疗可及性改善。
研究设计与样本
- 基于SEER数据库的趋势分析,评估肝细胞癌发病率、死亡率、肿瘤负荷、治疗及总生存。
- 采用逻辑回归分析与治愈性治疗及未治疗相关的因素,Cox回归分析与总生存相关的因素。
主要发现
- 基于发病率的死亡率2000至2013年上升,此后至2022年平台。
临床怎么用
- 临床需关注COVID-19后HCC早期检测和治愈性治疗机会的恢复。
- 对年轻、远处转移及非西班牙裔黑人患者,总生存改善提示应持续优化治疗可及性。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: With the COVID-19 pandemic, changes in liver disease etiologies, and expanded therapeutic options for hepatocellular carcinoma (HCC), recent trends in the incidence and mortality rates, tumor burden, treatment, and overall survival (OS) of HCC in the United States warrant investigation. METHODS: The Surveillance, Epidemiology, and End Results database was used to assess trends in incidence, mortality, tumor burden, and OS. Logistic regression analysis identified factors associated with curative treatment and no treatment, whereas Cox regression analysis identified factors associated with OS. RESULTS: HCC incidence rates increased from 2000 to 2014, plateaued from 2014 to 2019, and declined from 2019 to 2022 (annual percent change, -3.74%; 95% confidence interval [CI], -4.65% to -2.39%; P < .001). Incidence-based mortality increased from 2000 to 2013 and then plateaued through 2022. Compared with 2016 to 2019, the COVID-19 pandemic (2020-2022) was associated with lower odds of curative treatment (adjusted odds ratio [aOR], 0.87; 95% CI, 0.82-0.91; P < .001) and increased likelihood of no treatment (aOR, 1.48; 95% CI, 1.41-1.54; P < .001). OS improved from 2000 to 2019 but did not significantly change during 2020 to 2022 (vs 2016-2019: adjusted hazard ratio, 0.98; 95% CI, 0.95-1.01; P = .2). Conversely, OS improved among patients <50 years old, those with distant HCC, and non-Hispanic Blacks. Non-Hispanic Black race was not associated with worse survival (adjusted hazard ratio, 1.01; 95% CI, 0.99-1.03; P = .4). CONCLUSIONS: HCC incidence rates have started to decline, and incidence-based mortality has plateaued. Given lower early-stage detection and curative treatments during the COVID-19 pandemic, longer-term follow-up is warranted to assess the impact on survival. The reduced survival disparities between non-Hispanic Black and White patients may reflect improved equitable medical access.
引用
- Lee YT, Wang JJ, Danpanichkul P, et al. Recent Trends of Incidence, Mortality, Treatment, and Overall Survival of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2025. PMID: 41115581. doi:10.1016/j.cgh.2025.10.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。